Photodynamic therapy (PDT) is a recently approved treatment modality that involves the sequential administration of a photosensitizer or its precursor and light to generate singlet oxygen for treating diseased tissue. The use of topical aminolevulinic acid (ALA) and blue light for nonhypertrophic actinic keratoses currently represents the only approved dermatologic application for PDT in the U.S.A. ALA is a photosensitizer precursor that is metabolized by cells into protoporphyrin IX (PpIX), which can be subsequently activated by visible light. PDT with topical ALA has been shown to improve psoriasis, but post-treatment hyperpigmentation as well as inconsistent clinical responses despite repeated PDT sessions have limited the development of this treatment approach for psoriasis. Furthermore the use of topical PDT photosensitizers becomes somewhat impractical for treating larger body surface areas in patients with extensive psoriasis. We have recently shown that oral administration of ALA induces preferential accumulation of PpIX in psoriatic plaques. The objectives of this study were to evaluate the effects of PDT with blue light on psoriatic plaques after systemic ALA administration as well as to determine whether systemic ALA±PDT induces apoptosis in lesional T lymphocytes. It has been suggested that induction of apoptosis in lesional T lymphocytes may be indicative of longer remission time following treatment of psoriasis. J Invest Dermatol 119:77±83, 2002
MATERIALS AND METHODS
Patients This protocol involving human subjects was approved by the University of Montreal Hospital Center Ethics Committee, and informed consent was obtained from each patient before any procedures were performed. Three groups of four patients received a single oral ALA dose of either 5, 10, or 15 mg per kg. ALA in powder form was provided by DUSA Pharmaceuticals (Valhalla, NY) and mixed with orange juice immediately before administration. Patients were all asked to eat breakfast before coming to the clinic on the day of ALA administration. Baseline laboratory evaluation included complete blood count, aspartate amino transaminase (AST), alanine amino transaminase (ALT), alkaline phosphatase (AP), lactate dehydrogenase (LDH), g-glutamyl transferase (GGT), bilirubin, creatinine, urea, and urinalysis; AST, ALT, AP, GGT, LDH, and bilirubin were repeated 24 h and 72 h after ALA administration. On the day of ALA administration patients were kept under subdued lighting at the dermatology clinic for the entire day.
PDT session and psoriasis evaluation For each patient a total of 15 1.5 Q 1.5 cm square areas of psoriatic skin within three different plaques on the limbs were selected for PDT and exposed to blue light at 1, 3, or 6 h after ALA administration. A blue¯uorescent lamp (Blue-U, DUSA Pharmaceuticals) at irradiances of 9±11 mW per cm 2 was used for light exposure. The maximal output of this source is at 417 nm with a fullwidth half-maximum of 30 nm. The irradiance was measured each morning with an International Light IL 1700 radiometer (Newburyport, MA) equipped with a SED 240 detector, a UVB-1 ®lter, and a``Wide Eye'' Diffuser (W). The variation in irradiance according to differences in the size of limbs from patient to patient was less than 10%. The measured irradiance was multiplied by a factor of 1.65 following comparison of the International Light radiometer against a UDT S370 radiometer (Graseby Optronics, Orlando, FL). Five squares within each plaque were exposed to the following light¯uences: 1, 3, 6, 12, or 20 J per cm 2 for patients who received 5 or 10 mg per kg and 1, 2, 4, 8, or 10 J per cm 2 for patients who received 15 mg per kg. Psoriasis severity was assessed separately at each treatment site at baseline and at days 1, 3, 7, and 28 following PDT according to the visible degree of erythema, scaling, and thickness. Each of these features was evaluated on a scale of 0 (absence) to 4 (severe) and then added together to give the overall psoriasis severity score, which had a maximum possible score of 12.
In vivo¯uorescence spectroscopy PpIX¯uorescence in psoriatic and normal skin was monitored in vivo with a spectro¯uorometer equipped with a xenon lamp and a double monochromator (Skin Skan, SPEX Instruments, Edison, NJ). Fluorescence excitation was set at 407 nm and emission intensity at 635 nm was serially measured at baseline and after ALA administration for up to 24 h. These parameters were kept constant for every patient. In addition emission spectra were also speci®cally recorded before ALA administration as well as at 1, 3, and 6 h before and immediately after light exposure on the squares that were exposed to the lowest and highest¯uence. For all emission spectra, PpIX uorescence before and after light exposure was evaluated by measuring the area under the emission spectra between 620 and 650 nm after subtraction of the auto¯uorescence background. Quantitative¯uorescence microscopy Skin biopsies of psoriatic skin unexposed to blue light were taken before and at 1, 3, and 6 h after ALA administration. These biopsies were embedded in Frozen Section Medium (Stephens Scienti®c, Riverdale, NJ) and snap frozen in liquid nitrogen. Sections of 10 mm thickness from each frozen sample were cut with a cryostat, taking great care to minimize exposure of the sections to light in order to minimize PpIX photobleaching. Fluorescence images were generated with a Nikon Optiphot-2¯uorescence microscope equipped with a thermoelectrically cooled CCD camera (Model The sensitivity settings on the camera were identical for each slide. The integration time was 1 s. For¯uorescence recording, a 480 nm short pass (480DF60) excitation ®lter and a 635 T 10 nm bandpass (635DF55) emission ®lter were used (Harvard Apparatus, Montreal, Canada). After uorescence imaging, the slides were stained with toluidine blue and a standard light microscope image of the same area was captured without moving the microscope stage. All images were analyzed with Clemex vision software (Version 3.0.023, Longueuil, Quebec, Canada). Using this software, the stratum corneum and the rest of the epidermis were delineated on the toluidine blue images, which were then superimposed onto the¯uorescence images for quantifying¯uorescence intensity. The average¯uorescence intensity per pixel was calculated for the stratum corneum and the rest of the epidermis.
Detection of apoptosis in lesional lymphocytes by double sequential staining Twenty-four hours after ALA administration 4 mm skin biopsies were taken from one psoriatic square of each plaque exposed to light as well as from an unexposed plaque. For each PDTtreated plaque the biopsy was performed on the psoriatic square exposed to the highest¯uence that did not exhibit erythema. For patients treated with 5 mg per kg all biopsies were from the squares exposed to 20 J per cm 2 . For patients treated with 10 mg per kg all biopsies were performed on squares exposed to 20 J per cm 2 except three biopsies performed on plaques exposed at 3 h after ALA administration that were from squares exposed to 12 J per cm 2 . For patients treated with 15 mg per kg all biopsies were from squares exposed to 10 J per cm 2 except two from the same patient that were performed on squares exposed to 8 J per cm 2 for plaques exposed at 3 and 6 h after ALA administration. After formalin ®xation and paraf®n embedding, sections were cut from each specimen. Tissue sections where deparaf®nized, rehydrated in phosphate-buffered saline (PBS), and then processed to detect apoptotic cells with the TUNEL technique using the ApopTag Fluorescein in situ Apoptosis Detection Kit (Intergen Compagny, Purchase, NY). Fluorescence images demonstrating apoptotic cells were acquired with the Nikon Optiphot-2 uorescence microscope and recorded with the Clemex Vision Software as previously described. The same tissue sections were then left overnight at 4°C in their mounting medium, following which they were washed in PBS and processed for anti-CD3 immunohistochemistry the next day. Brie¯y, after blocking with the avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA) the sections where incubated for 1 h at room temperature with a polyclonal rabbit antihuman CD3 antibody at a dilution of 1:150 (Dako Diagnostic Canada, Mississauga, Ontario, Canada). After three washes in PBS, tissue sections were incubated for 30 min at room temperature with a biotin-conjugated goat antirabbit antibody diluted at 1:200 in 5% normal goat serum in PBS. Sections were washed in PBS and signal ampli®cation and visualization were carried out using an avidin/biotin/peroxidase complex and diaminobenzidine (Vector Laboratories). Slides were dehydrated in ethanol and xylene and mounted in VectaMount. Using the recorded image of the TUNEL technique a corresponding image of the same area was recorded after anti-CD3 immunohistochemistry. The number of TUNEL + positive CD3 lymphocytes per ®eld was counted.
Statistical analysis A one-way ANOVA for repeated measures was used for statistical analysis. A Bonferroni correction was applied when multiple comparisons were performed.
RESULTS
Oral ALA induces preferential accumulation of PpIX in psoriatic skin Following oral administration of ALA an emission spectrum typical of PpIX was observed on psoriatic plaques of patients who received 10 and 15 mg per kg. PpIX¯uorescence increased rapidly and signi®cantly over baseline in psoriatic skin after administration of 10 mg per kg (p = 0.002) and 15 mg per kg (p < 0.001) of ALA to reach a maximum at about 2±2.5 h (Fig 1) .
PpIX¯uorescence intensity did not increase signi®cantly after administration of 5 mg per kg of ALA. PpIX¯uorescence intensity also increased slightly in normal skin after administration of ALA at 10 mg per kg (p = 0.01) and 15 mg per kg (p = 0.005) (Fig 1) .
PDT with oral ALA and blue light induces mild erythema followed by improvement within psoriatic plaques Two patients who received 10 mg per kg developed mild erythema on the face 24 h after PDT. Despite clear instructions to avoid sunlight for the ®rst 2 d after ALA administration these two patients sustained direct sun exposure for about 5 min after leaving the clinic on the day of ALA administration. Blue light exposure was well tolerated by all patients. Only one patient who received 15 mg per kg complained of a mild but tolerable burning sensation during light exposure. Increased erythema compared to nonexposed psoriatic skin was observed in one patient treated with 15 mg per kg followed by 10 J per cm 2 of blue light at 3 and 6 h. Increased erythema was also noted on psoriatic skin for three patients treated with 10 mg per kg followed by exposure to 20 J per cm 2 of blue light 3 h later (Fig 2) .
Erythema was not observed on psoriatic skin of patients who received 5 mg per kg. Changes in plaque severity score were not statistically signi®cant for patients who received 5 mg per kg and 10 mg per kg (Fig 3) .
The best clinical improvement, however (Fig 2) , was seen in a patient who received 10 mg per kg. Individual clinical improve- Plaque severity decreased following PDT on 1.5 Q 1.5 cm areas of psoriatic skin after administration of 15 mg per kg of ALA. Improvement was not signi®cant for patients who received 5 mg per kg or 10 mg per kg. Plaque severity scores are given for 1 (gray), 6 (white), and 20 J per cm 2 (black) for patients who received 5 mg and 10 mg per kg and 1 (gray), 4 (white), and 10 J per cm 2 (black) for patients who received 15 mg per kg. Plaques were exposed to blue light at either 1 h, 3 h, or 6 h after ALA administration. Bars: SD; n = 4. VOL. 119, NO. 1 JULY 2002 ment was not as marked for patients treated with 15 mg per kg. For patients treated with 15 mg per kg the maximum improvement was noted for psoriatic skin exposed to 10 J per cm 2 of blue light 3 h after ALA administration with a 42% improvement in plaque severity compared to baseline (p < 0.001) (Fig 3) .
PDT at the highest¯uence induces photobleaching of PpIX Immediately after blue light exposure the red emission peak of PpIX intensity decreased in intensity to a level at which it was not detectable for most patients (Fig 4) .
Immediately after PDT performed at 3 h at the highest¯uence, PpIX¯uorescence intensity decreased by 100%, 97%, and 88% for patients who received 5, 10, and 15 mg per kg, respectively (Fig 5) . This was statistically signi®cant (p < 0.02) for all three ALA doses.
Epidermal PpIX accumulation in psoriatic skin is maximal 3 h after administration of ALA Following administration of ALA at 10 and 15 mg per kg an increase in red¯uorescence was mostly present in the epidermis (Fig 6) .
A granular¯uorescence was also observed in the dermis at 6 h but the resolution of the un®xed sections was not suf®cient to verify if it originated from immunocytes (Fig 6d) . PpIX microscope¯uorescence intensity did not increase signi®cantly in the stratum corneum or the epidermis following oral administration of ALA at 5 mg per kg (Fig 7) .
Following 10 mg per kg of ALA PpIX intensity increased signi®cantly in the epidermis (p = 0.03) to reach a maximum at 3 h, uorescence spectroscopy before and after PDT with 20 J per cm 2 for patients who received 5 mg per kg and 10 mg per kg, and after 10 J per cm 2 for patients who received 15 mg per kg. More than 85% photobleaching of PpIX was observed at all three time points for all ALA doses. A single emission spectrum was recorded from four patients for each time point. Bars: SD.
whereas the levels in the stratum corneum did not demonstrate signi®cant changes (Fig 7) . PpIX¯uorescence intensity increased by up to 2-fold in the epidermis after administration of 15 mg per kg of ALA to reach a maximum at 3 h (p = 0.005) (Fig 7) . PpIX intensity also increased in the stratum corneum at 1 h (p = 0.03) after ALA at 15 mg per kg (Fig 7) .
PDT with oral ALA induces apoptosis in lesional CD3+ lymphocytes TUNEL+ and CD3+ cells were seen in the dermis of psoriatic plaques of patients treated with ALA±PDT (Fig 8) .
The number of TUNEL+ and CD3+ cells per ®eld in the dermis did not differ signi®cantly from baseline for patients treated with 5 mg per kg or 15 mg per kg of ALA (Fig 9a) .
For patients treated with 10 mg per kg of ALA there was a signi®cant (p < 0.001) increase in the number of TUNEL+ and CD3+ cells per ®eld in plaques exposed to light 3 h after ALA administration compared to an unexposed plaque (Fig 9a) . The total number of TUNEL+ cells per ®eld in the epidermis was increased after ALA±PDT with 10 mg per kg (p = 0.003) and 15 mg per kg (p = 0.005) (Fig 9b) . This was signi®cant at 1 and 6 h after PDT for 15 mg per kg as well as 3 h for 10 mg per kg. The total number of TUNEL+ cells did not increase for patients treated with 5 mg per kg.
DISCUSSION
In this study we showed that blue light exposure of psoriatic plaques after oral administration of ALA induces apoptosis in lesional T lymphocytes under suberythemogenic conditions. T lymphocytes play a central role in the pathogenesis of psoriasis as suggested by clinical improvements reported following treatment with cyclosporine, interleukin-2±diphtheria toxin fusion protein (Gottlieb et al, 1995) , anti-CD4 (Rizova et al, 1994) , and antitumor necrosis factor a (Oh et al, 2000) monoclonal antibodies. Induction of apoptosis in lesional T lymphocytes has also been reported with other therapeutic modalities for psoriasis such as ultraviolet B (UVB) phototherapy and psoralen plus UVA (PUVA) therapy (Krueger et al, 1995; Coven et al, 1999) . PUVA therapy for example induces apoptosis in lymphocytes and has been associated with one of the longest periods of remission of the existing therapeutic modalities for psoriasis (Koo and Lebwohl, 1999) . In a previous study we failed to detect signi®cant PpIX accumulation in resting circulating CD4 and CD8 T lymphocytes (Bissonnette and Haishan, 2001 ). Activated T lymphocytes are more sensitive to ALA±PDT-induced apoptosis in vitro, however, than their resting counterpart (Rittenhouse-Diakun et al, 1995) . Activated T lymphocytes expressing CD25 are present in psoriatic skin and might therefore be sensitive to ALA±PDT (Gottlieb, 1997) . In this study a signi®cant increase in apoptotic CD3+ lymphocytes was only observed after ALA±PDT for patients treated with 10 mg per kg. This could be related to a higher photosensitizer±light combination and therefore a more important PDT effect in patients with 10 mg per kg. Patients treated with 10 mg per kg received as much as 20 J per cm 2 of blue light compared to 10 J per cm 2 for patients who received 15 mg per kg. Because of the relatively low penetration of blue light combined with light scattering from psoriatic scales it is possible that at 10 J per cm 2 not enough blue light reached the dermis to induce apoptosis in T lymphocytes. Clinically this resulted in an increase in erythema on the exposed plaques for three out of four patients treated with 10 mg per kg as opposed to none treated with 5 mg per kg and only one out of four treated with 15 mg per kg (light¯uences were lower at that higher ALA dose). The number of CD3+ TUNEL+ cells in the epidermis was too low to allow comparison of apoptosis in T lymphocytes from unexposed and exposed plaques. In addition the use of the TUNEL assay in psoriatic epidermis is more dif®cult as it is associated with a higher level of false positive because of the high number of actively dividing keratinocytes (Wrone-Smith et al, 1997). Nonetheless we observed an increase in the total number of TUNEL+ cells in the epidermis after PDT with 10 and 15 mg per kg. These cells could be apoptotic keratinocytes and/or T lymphocytes.
The overall tolerability of systemic ALA±PDT was excellent. In contrast to topical ALA±PDT for the treatment of psoriasis, which can be quite painful (Robinson et al, 1999) , patients did not complain of pain during light exposure. Oral ALA at 30±60 mg per kg has been associated with a high incidence of nausea, vomiting, as well as decreased blood pressure (Regula et al, 1995; Rick et al, 1997; Webber et al, 1997) . In this study only one patient who received 15 mg per kg experienced nausea, suggesting that lower ALA doses may be better tolerated for the treatment of psoriasis. Erythema and mild edema were the only signs observed on some of the exposed psoriatic skin areas after PDT; in all cases this was asymptomatic, and the appearance of psoriatic skin returned to baseline within 3 d after light exposure.
Clinical improvement as well as induction of apoptosis in T lymphocytes were thus observed without crusting and/or necrosis, which is often present after PDT for the treatment of skin tumors. Nonspeci®c photosensitivity has been reported in patients treated with ALA doses of 30±60 mg per kg (Regula et al, 1995; Sibille et al, 1995) . Facial erythema 24 h after administration of 30 mg per kg of ALA has also been observed even with exposure limited to ambient lighting (Bissonnette and Haishan, 2001 ). This was not observed in this study with the lower ALA doses administered. Slight facial erythema was observed in two patients, however, who were not compliant with sun avoidance measures, suggesting that even at 10 mg per kg patients need to avoid sunlight, especially in the ®rst 24 h. Further studies on facial accumulation of PpIX will need to be performed in order to fully evaluate the duration of photosensitivity.
PpIX accumulation in psoriatic skin was observed using in vivō uorescence spectroscopy for patients who received 10 and 15 mg per kg. This represents mostly epidermal PpIX as seen on uorescence micrographs. Although PpIX accumulation was not detected for patients who received 5 mg per kg this may have been due to the detection limit of our in vivo¯uorescence spectrometer. In addition the detection of PpIX levels after administration of low dose ALA can be confounded by the presence of endogenous PpIX in psoriatic scales (Bissonnette et al, 1998) . In a previous study using a different in vivo¯uorescence spectrometer we were able to detect Figure 6 . Following oral administration of ALA red¯uorescence accumulates mostly in the epidermis. Fluorescence micrographs showing epidermal red¯uorescence were generated before (a), as well as 1 h (b), 3 h (c), and 6 h (d) after ALA administration at 15 mg per kg. Granular¯uorescence was also present in the dermis at 6 h. Corresponding sections were stained with toluidine blue after¯uorescence microscopy (e, f, g, h).
PpIX¯uorescence in psoriatic skin of patients who received 20 and 30 mg per kg but not 10 mg per kg (Bissonnette and Haishan, 2001) , which demonstrates the importance of instrumental sensitivity. The absence of PpIX for patients who received 5 mg per kg also does not necessarily indicate that blue light exposure after this ALA dose would be ineffective, as in vivo¯uorescence spectroscopy predominantly measures PpIX accumulation within the epidermis. If suf®cient PpIX is present in lesional T lymphocytes after administration of ALA at 5 mg per kg to induce apoptosis upon light exposure, it would be clinically desirable to use lower ALA doses to avoid facial photosensitivity. The relatively low¯uences used with 5 mg per kg in this study may also explain the absence of increased apoptosis levels for T lymphocytes. Improvement in plaque severity was observed at the higher uences for patients treated with 15 mg per kg. Although encouraging, the presence of improvement cannot be interpreted as de®nite proof of ef®cacy due to the limited number of patients treated and the absence of a placebo-controlled group in this study. In order to assess ef®cacy, further studies will need to be performed comparing ALA±PDT to placebo. The presence of apoptosis in lesional T lymphocytes after systemic ALA±PDT suggests that this therapeutic modality could be useful for other diseases where T lymphocyte activation plays a central role, such as atopic dermatitis or alopecia areata. We have recently shown that ALA±PDT induces apoptosis in malignant T cells in vitro (Gad et al, 2001 ). This observation coupled with reports of improvement following topical Figure 7 . Epidermal levels of PpIX are increased after administration of ALA at 10 mg per kg and 15 mg per kg. PpIX levels were determined in the epidermis and stratum corneum with quantitative¯uorescence microscopy for patients who received ALA at 5 mg per kg, 10 mg per kg, and 15 mg per kg. Values represent average pixel intensity in the stratum corneum or the rest of the epidermis. Bars: SD; n = 16 sections from four patients for each dose and each time point. ALA±PDT in patients with mycosis fungoides (Wolf et al, 1994) also suggests that systemic ALA±PDT should be further explored for this indication.
In conclusion this study showed that PDT with blue light exposure after oral administration of ALA induces apoptosis in lesional T lymphocytes. The clinical improvement observed at the highest ALA doses and¯uences suggests that this therapeutic modality should be further investigated for the treatment of psoriasis.
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